A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

Winnie Byanyima says her organization has lost almost 50% of its funding, a gap that is undermining global efforts to combat ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday. It's the ...

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

The FDA approved lenacapavir (Yeztugo) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...